Table 1 Parameter values used to assess the cost-effectiveness of the CLF-IVR compared to the SOC in Uganda
Input parameters | Base case value | Sensitivity rangea | Reference |
|---|---|---|---|
Initial distribution | |||
 HIV | 1.00 | 0.8—1.2 | Assumption |
 AIDS | 0.00 | 0 | Assumption |
 Death | 0.00 | 0 | Assumption |
Transition probabilities, % | |||
 HIV state to AIDS state | 0.046 | 0.02—0.08 | [32] |
 HIV state-to-death state | 0.03 | 0.0063—0.082 | [33] |
 AIDS state-to-death state | 0.23 | 0.16—0.33 | [33] |
Effect of intervention | |||
 Viral load suppression rate, % | |||
  VL suppression rate –IVR | 0.74 | 0.68—0.79 | Primary study |
  VL suppression rate –SOC | 0.52 | 0.45—0.58 | Primary study |
DALY weights | |||
 DALY weight—HIV with ART | 0.27 | 0.18—0.38 | [38] |
 DALY weight—AIDS with ART | 0.08 | 0.05—0.11 | [38] |
Mean life expectancy at birth in Uganda (years) | |||
 Life expectancy at birth in Uganda | 64 | 51—78 | [36] |
Discount rate, % | |||
 Discount rate | 0.03 | 0.01—0.06 | [29] |
Costs, US $ | |||
 Annual operation cost –CLF-IVR | 36 | 29—43 | Primary study |
 ART duration in years over a lifetime –IVR | 486 | 389—583 | Assumption |
 ART duration in years over a lifetime – SOC | 898 | 718—1078 | Assumption |
 Annual cost of ART for a young adult living with HIV | 369 | 295—443 | [39] |